预约演示

FDA blocks approval of Regeneron's blood cancer drug over confirmatory trial enrollment

2024-03-26

加速审批临床1期临床3期免疫疗法

Regeneron was keen to stress in the release that the FDA “did not identify any approvability issues” with odronextamab’s clinical efficacy, safety, trial design, labeling or manufacturing.

Regeneron may have gotten ahead of itself with the eaFDA filing of bispecific antibody odronextamab to regodronextamaba move that might not surprise keen FDA watchers, the agency has issued two complete response letters over the timelines of ongoing phase 3 confirmatory trials for the drug.

Regeneron submitted an approval application in September 2023 for odronextamab to treatodronextamabth relapsed/refractory (R/R) follicular lymphoma (FL) oFDA/R diffuse large B-cell lymphoma (DLBCL), who have progressed after at least two prior systemic therapies. The application was supported by data from the phase 1 ELM-1 study and the phase 2 ELM-2 study.

Regeneron application was assessed by the FDA for an anticipated aodronextamabpproval decision on Marcrelapsed/refractory (R/R) follicular lymphoma (FL)atients diffuse large B-cell lymphoma (DLBCL)oma trials that formed part of the wide-ranging Olympia program. Enrollment in the dose-finding portion of these trials has already began, but the FDA decided that “the confirmatory portions of these trials should be underway and that the timelines to completion be agreed prior to resubmission” of the applications, according to Regeneron.

A critical facet of the accelerated approvFDAprocess is confirmatory trials that are meant to ultimately proRegeneronhe surrogate endpoint will translate to genuine clinical benefit. FDA CommilymphomaRobert Califf, M.D., has successfully advocated to have those trials underway before companies get accelerated approval, with the FDA's Center fFDABiologics Evaluation and Research Director Peter Marks, M.D., Ph.D., telling Fierce Biotech last year that this policy was a "work in progress."Regeneron

A meeting of the agency's oncologic drugs advisory committee in November 2023 also served as a reminder to cancer drug developers that the FDA is keeping a close eye on accelerated apFDAvals.FDA

For now, Regeneron only said that updates on the enrollment and regulatory timelines will be shared “later cancerear.”FDA

Still, itRegeneronve been worse. Regeneron was keen to stress in the release that the FDA “did not identify any approvability issues” with odronextamab’s clinical efficacy, safety, trial design, labeling or manufacturing.

This is not the first regulatory Regeneronor odronextamab, which was hit with a partiaFDAlinical hold back in 2020 over safety concerns. Buodronextamabhold was lifted in May 2021, the drug’s prospects had looked good, with the latest readout from ELM-2 in December 2023 showing objective and complete response rates of 52% and 31%, respectively.

The CD20xCD3 bispecific antibody is designed odronextamab20 on cancer cells with CD3-expressing T cells to facilitate local T-cell activation and cancer-cell killing.

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。

机构